United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $236.47, for a total transaction of $851,292.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,741.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Price Performance

United Therapeutics stock opened at $234.47 on Wednesday. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $261.54. The firm has a market capitalization of $11.03 billion, a price-to-earnings ratio of 11.82 and a beta of 0.52. The company has a fifty day simple moving average of $232.48 and a 200-day simple moving average of $228.69. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. During the same quarter in the prior year, the firm earned $2.67 earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wedbush reissued an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Finally, The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $213.00 to $215.00 in a report on Monday, February 12th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $294.25.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the business. Rise Advisors LLC purchased a new stake in shares of United Therapeutics during the first quarter worth $32,000. GAMMA Investing LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $43,000. C M Bidwell & Associates Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter valued at about $91,000. Ronald Blue Trust Inc. boosted its position in shares of United Therapeutics by 155.9% during the 3rd quarter. Ronald Blue Trust Inc. now owns 458 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 279 shares during the last quarter. Finally, Janiczek Wealth Management LLC boosted its position in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.